Navigation Links
Boehringer Ingelheim and Xencor Enter a Collaboration Agreement for the Development, Manufacture, and Supply of Biosuperior Monoclonal Antibodies
Date:2/21/2012

13 potentially resulting in key human pharmacokinetic data validating Xtend technology.

About Xencor, Inc.

Xencor, Inc. engineers superior biotherapeutics using its proprietary Protein Design Automation® technology platform, and is a leader in the field of antibody engineering to significantly improve antibody half-life, immune-regulatory function and potency. The company is advancing multiple XmAb® antibody drug candidates in the clinic, including XmAb®5871 targeting CD32b and CD19 for autoimmune diseases, and an anti-CD30 candidate XmAb®2513 for the treatment of Hodgkin's lymphoma. Xencor is also advancing a portfolio of biosuperior versions of blockbuster antibody drugs engineered for superior half-life and dosing schedule. Xencor has entered into multiple partnerships with industry leaders such as Amgen, Pfizer, Centocor, MorphoSys, Boehringer Ingelheim, CSL Ltd. and Human Genome Sciences. In these partnerships Xencor is applying its suite of proprietary antibody Fc domains to improve antibody drug candidates for traits such as sustained half-life and/or potency. For more information, please visit www.xencor.com.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates in 50 countries and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed for 125 years to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

Today, Boehringer Ingelheim is one of the world's leading companies for contract development and manufacture of biopharmaceuticals. All types of services from mammalian cell line or microbial strain development to final drug production can be delivered within a one-stop-shop concept. Boehringer
'/>"/>

SOURCE Xencor, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CompleGen Announces Successful Delivery of Its XenoGene™ Technology to Boehringer Ingelheim for Drug Discovery Under a Non-Exclusive Agreement.
2. AbGenomics International, Inc. Regains Global Rights to AbGn-168H from Boehringer Ingelheim
3. Boehringer Ingelheim Invests More Than $350 Million in 2011 U.S. Expansion Projects
4. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
5. Boehringer Ingelheim and Lilly to Feature Type 2 Diabetes Research in Presentations at the 47th Annual Meeting of the European Association for the Study of Diabetes
6. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
7. Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
8. Boehringer Ingelheim and Ashokas Changemakers Launch "Making More Health" Competition
9. Ashoka and Boehringer Ingelheim Announce a Global Partnership for "Making More Health"
10. Zealand Pharma and Boehringer Ingelheim Enter Into a Licence and Collaboration Agreement to Advance Novel Compounds to Treat Type-2 Diabetes and Obesity
11. Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its commitment ... (NYSE: PHG AEX: PHIA) today ... Administration (FDA) for its IQon Spectral CT , ... first-of-its kind technology adds a new dimension to Computed ... ability to characterize structures based on their material content ...
(Date:11/26/2014)... Pa. , Nov. 25, 2014  Unilife Corporation ... of injectable drug delivery systems, today announced that its ... to present at the Piper Jaffray 26th Annual Healthcare ... a.m. EST on Tuesday, December 2, 2014. ... Internet as a "live" listen only Webcast. To listen, ...
(Date:11/26/2014)... 25, 2014 Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... presentations at two upcoming investor conferences.  , 31 ... on Tuesday, December 2, 2014 at 6:45 a.m. EST / ... head of EUSA International, will provide an overview of the company ... Annual Piper Jaffray Healthcare Conference in New York, NY ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Jazz Pharmaceuticals Announces Participation in Two Investor Conferences 2
... Spencer Inc. (NYSE: CSA ) announced today ... of $0.10 per common share payable on October 20, 2010 ... covers the third quarter of 2010.   ... Spencer Inc. (NYSE: CSA ) is a fully-integrated, ...
... Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has ... ("FDA") of the successful completion of an inspection of ... product to market.  Under the Company,s Consent Decree, successful ... facilities are expected to be required before K-V is ...
Cached Medicine Technology:Cogdell Spencer Inc. Declares Quarterly Dividend 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 2K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 3K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 4K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 5K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 6K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 7K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market 8
(Date:11/27/2014)... babies and young children don,t need medicines if they ... says. Over-the-counter (OTC) cold and cough medicine should ... they could cause serious and potentially deadly side effects, ... colds a year, but children get them more often. ... give them pain relievers, decongestants and other medicines, but ...
(Date:11/27/2014)... November 27, 2014 The founders of VIM ... comfortable and high functioning compression socks, are proud to announce ... use an innovative Gradient Pressure (TM) knitting technology that is ... VIM & VIGR’s commitment to adding flair and style to ... functional recently caught the eye of a writer at ...
(Date:11/27/2014)... 27, 2014 Two international trainers and ... procedure will help one person with significant needs but ... Jivraj and Dr. Mamaly Reshad of the Anacapa Dental ... launched a website devoted to helping dentist learn about ... website would be devoted to helping a patient who ...
(Date:11/27/2014)... California (PRWEB) November 27, 2014 Developers and ... a new plugin entitled ProPip, taking FCPX to the next ... picture effect with a few clicks of a mouse,” said ... time saver that our users will appreciate.” , With ProPip ... customization leaving the possibilities truly endless. ProPip is great for ...
(Date:11/27/2014)... Philadelphia, PA (PRWEB) November 27, 2014 ... alongside volunteer Aria Health employees, prepared and donated ... to the Lutheran Settlement House , a non-profit, ... and families living in Philadelphia. The dinners were ... Settlement House Senior Center, and distributed to vulnerable ...
Breaking Medicine News(10 mins):Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Aria Health Prepares and Donates 200 Thanksgiving Dinners 2
... PROVIDENCE, R.I. A new nationwide clinician survey provides ... or treatment as usual for nonepileptic seizures (NES), laying ... treatments for this neuropsychiatric disorder. , There is ... resembles an epileptic seizure but is not caused by ...
... highlight how innovative solutions based on the Microsoft platform solve ... key industry challenges., ... Health & Life Sciences Developer and ... customers and industry partners speaking on the newest solutions and ...
... Meeting on April 22, 2008, the Centers for Medicare ... the establishment of a Healthcare Common Procedure Coding System ... the HCPCS is a standardized coding system that is ... in the Current Procedural Terminology (CPT) coding system assigned ...
... CSC to bundle healthcare services around intellectual property ... - Deward Watts appointed to lead practice ... Project Accelerate strategy, FALLS CHURCH, Va., April 21 ... of the company,s new,Healthcare Sector, a dedicated vertical business unit ...
... Milestone,Scientific Inc. (OTC Bulletin Board: MLSS), the recognized ... Device &,Diagnostic Industry (MD&DI) magazine has distinguished the ... Design Excellence Award (MDEA) in the,"dental instruments, equipment ... receive an MDEA this year, Milestone,s STA System ...
... MADISON, N.J., April 21 Quest Diagnostics,Incorporated (NYSE: ... and services, announced that for the first quarter,ended March ... $0.72 per diluted share, compared to $108 million, or ... Included in the results for the first,quarter of 2007 ...
Cached Medicine News:Health News:Survey offers first-ever look at treatment practices for nonepileptic seizures 2Health News:Microsoft Health & Life Sciences Developer and Solutions Conference to Feature the Latest Microsoft-Based Software Solutions 2Health News:Medicare to consider public opinion about medical maggots 2Health News:Medicare to consider public opinion about medical maggots 3Health News:CSC Launches Global Healthcare Sector 2Health News:CSC Launches Global Healthcare Sector 3Health News:Milestone Scientific's STA(TM) System Wins 2008 Medical Design Excellence Award 2Health News:Milestone Scientific's STA(TM) System Wins 2008 Medical Design Excellence Award 3Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 2Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 3Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 4Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 5Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 6Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 7Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 8Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 9Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 10Health News:Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008 11
The Telescopic Plate Spacer (TPS - C) Implants is an expandable titanium spacer designed to stabilize the spine following corpectomy/ vertebrectomy procedures....
... generation interbody fusion device. Rhakoss implants ... alternative to titanium/carbon fiber cages and ... the best features of first generation ... disadvantages of current available materials, such ...
Fortitude as a unique complement to the spinal concepts family of products....
As a unique complement to the spinal concepts family of products....
Medicine Products: